Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Bakkenolide B; Fukinolide

$730

  • Brand : BIOFRON

  • Catalogue Number : AV-B04203

  • Specification : 98%

  • CAS number : 18455-98-6

  • Formula : C22H30O6

  • Molecular Weight : 390.47

  • PUBCHEM ID : 11165211

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B04203

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

390.47

Appearance

Powder

Botanical Source

Structure Type

Sesquiterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC=C(C)C(=O)OC1CCC(C2(C1C(C3(C2)C(=C)COC3=O)OC(=O)C)C)C

Synonyms

(3R,3'R,3a'R,4'S,7'S,7a'R)-3'-Acetoxy-7',7a'-dimethyl-4-methylene-2-oxodecahydrospiro[furan-3,2'-inden]-4'-yl (2Z)-2-methyl-2-butenoate/2-Butenoic acid, 2-methyl-, (3R,3'R,3a'R,4'S,7'S,7a'R)-3'-(acetyloxy)decahydro-7',7'a-dimethyl-4-methylene-2-oxospiro[furan-3(2H),2'-[2H]inden]-4'-yl ester, (2Z)-

IUPAC Name

[(2R,3R,3aR,4S,7S,7aR)-3-acetyloxy-7,7a-dimethyl-4'-methylidene-2'-oxospiro[3,3a,4,5,6,7-hexahydro-1H-indene-2,3'-oxolane]-4-yl] (Z)-2-methylbut-2-enoate

Applications

657

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

217.1±30.2 °C

Boiling Point

503.0±50.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C22H30O6/c1-7-12(2)19(24)28-16-9-8-13(3)21(6)11-22(14(4)10-26-20(22)25)18(17(16)21)27-15(5)23/h7,13,16-18H,4,8-11H2,1-3,5-6H3/b12-7-/t13-,16-,17+,18+,21+,22+/m0/s1

InChl Key

AVAGQVZSHJYDED-RRIKAWJQSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:18455-98-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31804586

Abstract

The improvement of body’s own immune system is considered one of the safest approaches to fight against cancer and several other diseases. Excessive catabolism of the essential amino acid, L-tryptophan (L-Trp) assists the cancer cells to escape normal immune obliteration. The formation of disproportionate kynurenine and other downstream metabolites suppress the T cell functions. Blocking of this immunosuppressive mechanism is considered as a promising approach against cancer, neurological disorders, autoimmunity, and other immune-mediated diseases. Overexpression of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme is directly related to the induction of immunosuppressive mechanisms and represents an important therapeutic target. Several classes of small molecule-based IDO1 inhibitors have been already reported, but only few compounds are currently being evaluated in various stages of clinical trials as adjuvants or in combination with chemo- and radiotherapies. In the quest for novel structural class(s) of IDO1 inhibitors, we developed a series of 4,5-disubstituted 1,2,3-triazole derivatives. The optimization of 4,5-disubstituted 1,2,3-triazole scaffold and comprehensive biochemical and biophysical studies led to the identification of compounds, 3i, 4i, and 4k as potent and selective inhibitors of IDO1 enzyme with IC50 values at a low nanomolar level. These potent compounds also showed strong IDO1 inhibitory activities in MDA-MB-231 cells with no/negligible level of cytotoxicity. The T cell activity studies revealed that controlled regulation of IDO1 enzyme activity in the presence of these potent compounds could induce immune response against breast cancer cells. The compounds also showed excellent in vivo antitumor efficacy (of tumor growth inhibition = 79-96%) in the female Swiss albino mice. As a consequence, this study describes the first example of 4,5-disubstituted 1,2,3-triazole based IDO1 inhibitors with potential applications for immunotherapeutic studies.

Subject terms: Drug discovery and development, Oxidoreductases

Title

4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth

Author

Subhankar Panda,#1 Nirmalya Pradhan,#1 Soumya Chatterjee,2 Sudhir Morla,3 Abhishek Saha,1 Ashalata Roy,1 Sachin Kumar,3 Arindam Bhattacharyya,corresponding author2 and Debasis Mannacorresponding author1

Publish date

2019;

PMID

26770452

Abstract

Background: Quantification of the association between the consumption of vegetables and risk of age-related cataract is still conflicting. We therefore conducted a meta-analysis to summarize the evidence from epidemiological studies of vegetables consumption with the risk of age-related cataract. Methods: Pertinent studies were identified by searching of PubMed and Web of Science. The random effect model was used to combine the results. Meta-regression and subgroups analyses were used to explore potential sources of between-study heterogeneity. Publication bias was estimated using Egger’s regression asymmetry test. Results: Finally, 9 articles involving 6,464 cataract cases and 112,447 participants were included in this meta-analysis. Pooled results suggested that highest vegetables consumption level compared with lowest level was inverse with the risk of age-related cataract [summary relative risk (RR) = 0.723, 95% CI = 0.594-0.879, I2 = 72.8%]. The associations were also significant in America [summary RR = 0.872, 95% CI = 0.791-0.960] and Europe [summary RR = 0.507, 95% CI = 0.416-0.619], but not in the other population. No publication bias was found. Conclusions: Higher vegetables consumption might be inversely associated with risk of cataract.

KEYWORDS

Vegetables, age-related cataract, meta-analysis

Title

Association between vegetables consumption and the risk of age-related cataract: a meta-analysis

Author

Guoqiang Huang,1 Laiwei Wu,2 Lianghui Qiu,1 Jiangfeng Lai,1 Zhengying Huang,3 and Li’an Liao4

Publish date

2015;

PMID

32231712

Abstract

Background:
Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed the risk of these events and the overall survival (OS) benefit in breast cancer patients treated with AI, compared with TAM-treated patients, in a large population-based cohort.

Methods:
This observational cohort study included women diagnosed with breast cancer and treated with TAM or AI. Data were extracted from primary care records in a population database (SIDIAP, System for the Development of Research in Primary Care). Incidence rates of study outcomes are reported. Survival analyses included Kaplan-Meier estimation and Cox proportional hazards models. Sensitivity analysis was carried out, using Fine and Gray models to account for competing risk of death. Confounding was minimized using propensity score adjustment and inverse probability weighting (IPW) adjustment.

Results:
Data from 3082 postmenopausal women treated with TAM, and 18,455 treated with AI, were available. Adjusted hazard ratios (HRs) [95% confidence interval (CI)] for AI users, compared with TAM group, were 0.93 (95%CI 0.69-1.26) for thromboembolic events (TEEs); 1.13 (95%CI 0.79-1.63) for cardiovascular events, and 0.76 (95%CI 0.70-0.82) for mortality. Additional analyses using competing risk analysis had similar results, while IPW adjustment showed a potential risk of pulmonary embolism (PE) [2.26 (95%CI 1.02-4.97)] in AI-treated patients.

Conclusions:
AI users had >20% lower all-cause mortality compared with TAM users, without increasing risk to experience cardiovascular and TEEs. This would locate AI therapy on the first line in clinical practice. Thus, AI might be the most preferable option in adjuvant hormonal therapy choice.

KEYWORDS

aromatase inhibitor, breast cancer, cardiovascular events, overall mortality, tamoxifen, thromboembolic events

Title

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study

Author

Marta Pineda-Moncusi, Natalia Garcia-Giralt, Adolfo Diez-Perez, Ignasi Tusquets, Sonia Servitja, Joan Albanell, Daniel Prieto-Alhambra, and Xavier Nogues

Publish date

2020